Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight
F. Revel, J‐L Moreau, Bruno Pouzet, et al.
Molecular Psychiatry (2012) Vol. 18, Iss. 5, pp. 543-556
Open Access | Times Cited: 257

Showing 1-25 of 257 citing articles:

Dopamine receptors – IUPHAR Review 13
Jean‐Martin Beaulieu, Stefano Espinoza, Raul R. Gainetdinov
British Journal of Pharmacology (2014) Vol. 172, Iss. 1, pp. 1-23
Open Access | Times Cited: 454
Trace Amines and Their Receptors
Raul R. Gainetdinov, Marius C. Hoener, Mark D. Berry
Pharmacological Reviews (2018) Vol. 70, Iss. 3, pp. 549-620
Open Access | Times Cited: 321
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Robert A. McCutcheon, Richard S.E. Keefe, Philip McGuire
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1902-1918
Open Access | Times Cited: 315
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Elena Dale, Benny Bang‐Andersen, Connie Sanchéz
Biochemical Pharmacology (2015) Vol. 95, Iss. 2, pp. 81-97
Open Access | Times Cited: 214
Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges
Mark D. Berry, Raul R. Gainetdinov, Marius C. Hoener, et al.
Pharmacology & Therapeutics (2017) Vol. 180, pp. 161-180
Open Access | Times Cited: 199
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2Receptor Mechanism of Action
Nina Dedic, Philip Jones, Seth C. Hopkins, et al.
Journal of Pharmacology and Experimental Therapeutics (2019) Vol. 371, Iss. 1, pp. 1-14
Open Access | Times Cited: 151
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 49
Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments
Stephen R. Marder, Daniel Umbricht
Schizophrenia Research (2023) Vol. 258, pp. 71-77
Open Access | Times Cited: 42
Psychotropic Drug–Related Weight Gain and Its Treatment
Roger S. McIntyre, Angela T.H. Kwan, Joshua D. Rosenblat, et al.
American Journal of Psychiatry (2024) Vol. 181, Iss. 1, pp. 26-38
Closed Access | Times Cited: 42
The Case for TAAR1 as a Modulator of Central Nervous System Function
Grazia Rutigliano, Alice Accorroni, Riccardo Zucchi
Frontiers in Pharmacology (2018) Vol. 8
Open Access | Times Cited: 139
Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors
Damiana Leo, Liudmila Mus, Stefano Espinoza, et al.
Neuropharmacology (2014) Vol. 81, pp. 283-291
Closed Access | Times Cited: 138
Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications
Yue Pei, Aman Asif-Malik, Juan J. Canales
Frontiers in Neuroscience (2016) Vol. 10
Open Access | Times Cited: 120
Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers
Anja Harmeier, Stefan Obermueller, Claas A. Meyer, et al.
European Neuropsychopharmacology (2015) Vol. 25, Iss. 11, pp. 2049-2061
Closed Access | Times Cited: 110
TAAR1 Modulates Cortical Glutamate NMDA Receptor Function
Stefano Espinoza, Gabriele Lignani, Lucia Caffino, et al.
Neuropsychopharmacology (2015) Vol. 40, Iss. 9, pp. 2217-2227
Open Access | Times Cited: 109
d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
Danilo De Gregorio, Stefano Comai, Luca Posa, et al.
International Journal of Molecular Sciences (2016) Vol. 17, Iss. 11, pp. 1953-1953
Open Access | Times Cited: 105
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Amanda Krogmann, Luisa Peters, Laura von Hardenberg, et al.
CNS Spectrums (2019) Vol. 24, Iss. S1, pp. 38-69
Open Access | Times Cited: 103
In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1
Linda D. Simmler, D. Buchy, Sylvie Chaboz, et al.
Journal of Pharmacology and Experimental Therapeutics (2016) Vol. 357, Iss. 1, pp. 134-144
Open Access | Times Cited: 100
Incretin-like effects of small molecule trace amine-associated receptor 1 agonists
S. Raab, Haiyan Wang, Sabine Uhles, et al.
Molecular Metabolism (2015) Vol. 5, Iss. 1, pp. 47-56
Open Access | Times Cited: 96
The emerging roles of human trace amines and human trace amine-associated receptors (hTAARs) in central nervous system
Muhammad Zahid Khan, Waqas Nawaz
Biomedicine & Pharmacotherapy (2016) Vol. 83, pp. 439-449
Closed Access | Times Cited: 95
Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1
Stefano Espinoza, Valentina Ghisi, Marco Emanuele, et al.
Neuropharmacology (2015) Vol. 93, pp. 308-313
Closed Access | Times Cited: 94
The hallucinogen d -lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT 1A , D 2 and TAAR 1 receptors
Danilo De Gregorio, Luca Posa, Rafael Ochoa‐Sanchez, et al.
Pharmacological Research (2016) Vol. 113, pp. 81-91
Closed Access | Times Cited: 93
Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits
David R. Goldsmith, Mark Hyman Rapaport
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 84
Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders
Daniil Grinchii, Eliyahu Dremencov
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9532-9532
Open Access | Times Cited: 79
Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
Nina Dedic, Heather Dworak, Courtney Zeni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13185-13185
Open Access | Times Cited: 77
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 59
Page 1 - Next Page

Scroll to top